

# Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019

https://marketpublishers.com/r/T3B7464685A1EN.html

Date: December 2019

Pages: 64

Price: US\$ 3,500.00 (Single User License)

ID: T3B7464685A1EN

## **Abstracts**

Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019

### **SUMMARY**

According to the recently published report 'Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019'; Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Transforming growth factor beta 2 (TGF-?2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth.

The report 'Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or



Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Dermatology, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Age Related Macular Degeneration, Choroidal Neovascularization, Colorectal Cancer, Diabetic Macular Edema, Fibrosis, Head And Neck Cancer, High-Grade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Proliferative Vitreoretinopathy (PVR), Scar and Solid Tumor.

### **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)

The report reviews Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics and enlists all



their major and minor projects

The report assesses Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics

#### **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development



## landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



## **Contents**

Introduction

Global Markets Direct Report Coverage

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or

Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Overview

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or

Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or

Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or

Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Companies

Involved in Therapeutics Development

Avacta Life Sciences Ltd

Genzyme Corp

Isarna Therapeutics GmbH

Novartis AG

Oncotelic Inc

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or

Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Drug Profiles

Antisense Oligonucleotide 1 to Inhibit TGFB2 for Oncology - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

AVA-027 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

decorin - Drug Profile



**Product Description** 

Mechanism Of Action

**R&D Progress** 

fresolimumab - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

ISTH-0036 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

ISTH-0047 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

LNAOT-101 - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

trabedersen - Drug Profile

**Product Description** 

Mechanism Of Action

R&D Progress

XOMA-089 - Drug Profile

**Product Description** 

Mechanism Of Action

**R&D Progress** 

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Dormant Products

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Discontinued Products

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Product Development Milestones

Featured News & Press Releases

Dec 02, 2019: Mateon Therapeutics team publishes three new peer-reviewed oncology articles outlining the clinical impact Potential of its first-in-class anti-TGF-beta RNA



therapeutic OT101/Trabedersen

Nov 18, 2019: Mateon Therapeutics to present new and updated data for OT101 (Trabedersen) activity against brain tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

Oct 23, 2019: New research study provides target validation for Mateon's first-in-class RNA therapeutic OT101 for the treatment of difficult to treat forms of childhood brain tumor

Sep 23, 2019: FDA grants Pediatric Disease Designation for Mateons OT101

Jul 30, 2019: Oncotelic provides clinical development update on patented lead anticancer drug candidate OT101

Jul 16, 2019: Internationally recognized top neurosurgeon joins the Medical Advisory Board of Oncotelic

Jun 03, 2019: WideTrial partners With Oncotelic to bring expanded access platform to cancer

Mar 04, 2019: Oncotelic reports clinical validation of drug induce xenogenization (DIX) for treatment of glioblastoma and pancreatic cancer (PC)

Feb 13, 2019: Oncotelic reports that itS proprietary in-situ cancer vaccine improved survival over standard chemotherapy in patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma

Jan 22, 2019: Oncotelic announces appointment of Fatih Uckun MD PhD to Chief Medical Officer

Dec 26, 2018: Scientists develop sight-saving treatment for eye infection

May 15, 2017: Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO 2017 Annual Conference

Mar 30, 2017: Oncotelic and Autotelic to present data on OT-101 program at 2017 American Association for Cancer Research Annual Meeting

Sep 02, 2016: Oncotelic and Autotelic Announce Clinical Data Supporting IL-8 Spike as a Prognostic Biomarker for Immunotherapy

May 04, 2016: Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma at ARVO 2016 Annual Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

**Expert Panel Validation** 

Contact Us

Disclaimer







## **List Of Tables**

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Avacta Life Sciences Ltd, H2 2019

Pipeline by Genzyme Corp, H2 2019

Pipeline by Isarna Therapeutics GmbH, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Oncotelic Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019



# **List Of Figures**

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

## **COMPANIES MENTIONED**

Avacta Life Sciences Ltd Genzyme Corp Isarna Therapeutics GmbH Novartis AG Oncotelic Inc



## I would like to order

Product name: Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019

Product link: https://marketpublishers.com/r/T3B7464685A1EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/T3B7464685A1EN.html">https://marketpublishers.com/r/T3B7464685A1EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to  $+44\ 20\ 7900\ 3970$ 

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms